Dual-function antibodies targeting VEGFR2 and VEGFR3
US11623960B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 20, 2019 |
| Grant date | Apr 11, 2023 |
| Priority date | — |
| Expiry date | Jun 16, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N9/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An isolated antibody, comprising heavy chain complementary determining regions CDR1, CDR2, and CDR3 from a heavy chain variable region sequence having SEQ ID NO: 1 or 3; light chain complementary determining regions CDR1, CDR2, and CDR3 from a light chain variable region sequence having SEQ ID NO: 2 or 4; wherein the antibody binds specifically to both vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.